Kiran Hari Lagisetty, MD
Dr. Kiran Hari Lagisetty is a general thoracic surgeon at the University of Michigan’s Rogel Cancer Center and the Ann Arbor Veteran’s Hospital. In addition to his role as Assistant Professor of Surgery, he is a valuable member of the Rogel Cancer Center’s Thoracic Oncology Program, the Transplant Center, and the Thoracic Surgery Department. His clinical practice encompasses all aspects of general thoracic surgery but is focused on thoracic malignancies including malignant pleural mesothelioma, esophageal cancer, and lung cancer.[1]
Dr. Lagisetty’s clinical specializations include benign and malignant lung resections, minimally invasive robotic techniques, and lung transplantation. His membership in the multidisciplinary teams that care for malignant pleural mesothelioma and lung cancer patients has him meeting with colleagues to discuss patient treatment options, including clinical trials.
Education and Career
Dr. Lagisetty earned his undergraduate degree at the University of Alabama at Birmingham, where he earned a bachelor of arts in Philosophy. He continued to study there for his medical degree, then completed an internship and General Surgery residency at Beth Israel Deaconess Medical Center/Harvard Medical School. He spent two years at the National Institutes of Health, studying tumor immunology and genetic engineering/therapy as a clinical research fellow, the completed an additional two-year Thoracic Surgery fellowship at the University of Michigan.[1]
Dr. Lagisetty is board-certified in Surgery and Thoracic and Cardiac Surgery. He is a member of the American College of Surgeons and the Society of Thoracic Surgeons as well as the Michigan Society of Thoracic and Cardiovascular Surgeons.
Research Interests
Dr. Lagisetty’s research focuses on immunologic determinates of treatment resistance in lung and esophageal cancer as well as quality improvement in outcomes for patients being treated for lung and esophageal cancer. He has presented to the Society for Thoracic Surgeons on the topic of Novel Technology in Non-Small Cell Lung Cancer and published numerous articles and studies in respected medical journals, including:[1]
Clinically Occult Diffuse Pleural Mesothelioma in Patients Presenting With Spontaneous Pneumothorax. Am J Clin Pathol. 2023 Sept. 1. Fels Elliott DR, Konopka KE, Hrycaj SM, Lagisetty KH, Myers JL, Farver CF, Huang T.;160(3):322-330. doi: 10.1093/ajcp/aqad057. PMID: 37256702.
Higher Long-term Quality of Life Metrics After Video-Assisted Thoracoscopic Surgery Lobectomy Compared With Robotic-Assisted Lobectomy. Ann Thorac Surg. 2022 May. Williams AM, Zhao L, Grenda TR, Kathawate RG, Biesterveld BE, Bhatti UF, Carrott PW, Lagisetty KH, Chang AC, Lynch W, Lin J, Reddy RM.;113(5):1591-1597. doi: 10.1016/j.athoracsur.2020.05.033. Epub 2020 Jun 26. PMID: 32599037.
Quality improvement mechanisms to improve lymph node staging for lung cancer: Trends from a statewide database. J Thorac Cardiovasc Surg. 2023 Aug 23. Kalata S, Reddy RM, Norton EC, Clark MJ, He C, Leyden T, Adams KN, Popoff AM, Lall SC, Lagisetty KH.:S0022-5223(23)00744-4. doi: 10.1016/j.jtcvs.2023.08.033. Epub ahead of print. PMID: 37625618.
The Role of Lung Cancer Surgical Technique on Lymph Node Sampling and Pathologic Nodal Upstaging. Ann Thorac Surg. 2023 May. Kalata S, Mollberg NM, He C, Clark M, Theurer P, Chang AC, Welsh RJ, Lagisetty KH.;115(5):1238-1245. doi: 10.1016/j.athoracsur.2022.09.040. Epub 2022 Oct 12. PMID: 36240869.
